Overview of Intracoronary Brachytherapy for in-Stent Restenosis of a Drug-Eluting Stent
Authors
Abstract:
Percutaneous coronary intervention with stenting is considered recently as the most common procedure for the treatment of symptomatic coronary. The article reviewed 41 studies published during 1997-2019 on intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent. Intracoronary radiation therapy was finally confirmed in the setting of in-stent restenosis using as adjunctive therapy. Irradiation dose to vessels may result in fibrosis, which can, in turn, cause the late formation of an aneurysm due to the weakness of the vessel wall. Intracoronary brachytherapy is a critical treatment which should not be ignored.
similar resources
Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
PURPOSE Given the limited salvage options for in-stent restenosis (ISR) of drug-eluting stents (DES), our high-volume cardiac catheterization laboratory has been performing intracoronary brachytherapy (ICBT) in patients with recurrent ISR of DES. This study analyzes their baseline characteristics and assesses the safety/toxicity of ICBT in this high-risk population. METHODS AND MATERIALS A re...
full textDrug-Eluting Stent Restenosis
OBJECTIVES We sought to determine if the angiographic pattern of in-stent restenosis in drug-eluting stents (DES) maintains its prognostic importance. BACKGROUND The pattern of restenosis in the bare-metal stent era had a significant impact on therapeutic outcomes. METHODS We identified a total of 250 consecutive restenotic lesions in 203 patients (66.4% sirolimuseluting stents and 33.6% paclit...
full textIntracoronary brachytherapy for the treatment of complex in-stent restenosis.
T he development of an effective strategy for management of in-stent restenosis (ISRS) following ‘‘bare metal’’ stenting has proved difficult. Standard percutaneous therapy for ISRS leads to re-restenosis rates above 50% and consequently represents a poor treatment option. At present the ‘‘gold standard’’ treatment for ISRS is vascular brachytherapy (VBT), with re-restenosis rates falling to be...
full textDrug-eluting stent restenosis rates?
The article by Lemos et al1 describing coronary restenosis after implantation of sirolimus-eluting stents is of great interest. With the increasing demand for drug-eluting stents (DES) and the recent formation of guidelines for their use, confirmation of their continued efficacy in reducing restenosis is important. Therefore, registry data from a large patient population such as the Thoraxcente...
full textIntravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis.
Drug-eluting stents (DESs), although promising technology, still are associated with restenosis; therefore, we evaluated the safety and efficacy of intravascular radiation therapy for the treatment of DES in-stent restenosis (ISR). Treatment of DES ISR has not been established, although intravascular radiation therapy is an effective treatment for patients with ISR of bare metal stents. Other m...
full textIn-stent restenosis in the drug-eluting stent era.
The introduction of the drug-eluting stent (DES) proved to be an important step forward in reducing rates of restenosis and target lesion revascularization after percutaneous coronary intervention. However, the rapid implementation of DES in standard practice and expansion of the indications for percutaneous coronary intervention to high-risk patients and complex lesions also introduced a new p...
full textMy Resources
Journal title
volume 7 issue 1
pages 400- 405
publication date 2019-03-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023